Peptide-based cancer vaccines
Current opinion in immunology, 1996•Elsevier
The application of molecularly defined vaccines composed of a limited number of tumor-
specific T cell epitopes has resulted in protective intitumor T cell innumity in several mouse
tumor models. The first encouraging results with such vaccines have been obtained in
human beings. The development of the next generation of rationally designed vaccines that
are both effective and safe for application in a clinical setting requires comparison of
different modes of delivery of tumor-associated T cell epitopes in multiple epitope constructs
specific T cell epitopes has resulted in protective intitumor T cell innumity in several mouse
tumor models. The first encouraging results with such vaccines have been obtained in
human beings. The development of the next generation of rationally designed vaccines that
are both effective and safe for application in a clinical setting requires comparison of
different modes of delivery of tumor-associated T cell epitopes in multiple epitope constructs
The application of molecularly defined vaccines composed of a limited number of tumor-specific T cell epitopes has resulted in protective intitumor T cell innumity in several mouse tumor models. The first encouraging results with such vaccines have been obtained in human beings. The development of the next generation of rationally designed vaccines that are both effective and safe for application in a clinical setting requires comparison of different modes of delivery of tumor-associated T cell epitopes in multiple epitope constructs
Elsevier
